结节病患者的远期不良心脏结局
该队列研究基于丹麦全国登记数据,纳入1996至2016年新诊断的结节病患者,并按年龄、性别和合并症1:4匹配背景人群,比较远期心力衰竭及其他不良心脏结局风险。中位随访8.2年,结节病患者心力衰竭、ICD植入/室性心律失常/心脏骤停复合终点、起搏器植入/房室传导阻滞/窦房结功能障碍复合终点、心房颤动或扑动及全因死亡的10年绝对风险均高于匹配对照。
要点
- 结节病患者10年心衰绝对风险为3.18%,高于背景人群的1.72%。
- 结节病患者10年全因死亡风险为10.88%,高于背景人群的7.43%。
- ICD植入、室性心律失常和心脏骤停复合终点及起搏器植入、房室传导阻滞和窦房结功能障碍复合终点风险均升高。
核心结论
- 与匹配的对照人群相比,结节病患者发生心力衰竭和其他不良心脏结局的风险更高。
研究设计与样本
- 基于丹麦全国登记数据的队列研究,纳入1996至2016年新诊断的年龄≥18岁结节病患者,按年龄、性别和合并症1:4匹配无结节病的背景人群。
- 共11,834例结节病患者与47,336例背景人群匹配,中位年龄42.8岁(25至75百分位:33.1至55.8岁),54.3%为男性,中位随访8.2年。
主要发现
- 结节病患者心力衰竭10年绝对风险为3.18%(95%CI:2.83%至3.57%),背景人群为1.72%(95%CI:1.58%至1.86%)。
- 结节病患者ICD植入、室性心律失常和心脏骤停复合终点10年绝对风险为0.96%(95%CI:0.77%至1.18%),背景人群为0.45%(95%CI:0.38%至0.53%)。
- 结节病患者起搏器植入、房室传导阻滞和窦房结功能障碍复合终点10年绝对风险为0.94%(95%CI:0.75%至1.16%),背景人群为0.51%(95%CI:0.44%至0.59%)。
- 结节病患者心房颤动或扑动10年绝对风险为3.44%(95%CI:3.06%至3.84%),背景人群为2.66%(95%CI:2.49%至2.84%)。
- 结节病患者全因死亡10年绝对风险为10.88%(95%CI:10.23%至11.55%),背景人群为7.43%(95%CI:7.15%至7.72%)。
临床怎么用
- 对结节病患者应关注心力衰竭、心律失常和传导障碍的长期风险,并在随访中保持相应监测意识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis. OBJECTIVES: The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects. METHODS: In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis. RESULTS: Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population. CONCLUSIONS: Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.
引用
- Yafasova A, Fosbøl EL, Schou M, et al. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. J Am Coll Cardiol. 2020. PMID: 32792073. doi:10.1016/j.jacc.2020.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。